Search Result

Search Result

Results for "

progesterone receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Progesterone Receptor (12) Androgen Receptor (1) Autophagy (5) Endogenous Metabolite (3) Glucocorticoid Receptor (6) GnRH Receptor (1) Isotope-Labeled Compounds (2) Mineralocorticoid Receptor (6) NO Synthase (5)
By Research Areas:	Cancer (7) Cardiovascular Disease (5) Endocrinology (11) Inflammation/Immunology (2) Metabolic Disease (1)

20

Inhibitors & Agonists

5

Isotope-Labeled Compounds

Targets Recommended: Progesterone Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Asoprisnil J867	Progesterone Receptor	Endocrinology
Asoprisnil (J867), a selective **progesterone receptor** modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human .

Mifepristone Maximum Cited Publications 35 Publications Verification RU486; RU 38486	Endogenous Metabolite Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-119482

Cymipristone

Progesterone Receptor Others

Cymipristone (ZXH-951), a progesterone receptor antagonist, is used potentially for termination of intrauterine pregnancy .

PR antagonist 1	Progesterone Receptor	Endocrinology
PR antagonist 1 (compound 8) is a selective progesterone receptor (PR) antagonist, and can be used for the research of a variety of progesterone-related diseases and disorders such as endometriosis and uterine fibroids .

HY-113889

ZK112993

Progesterone Receptor Cancer

ZK112993 is a potent progesterone receptor (PR) antagonist. ZK112993 significantly inhibits the growth of T61 human tumors in nude mice .

PF-02413873 PF-2413873	Progesterone Receptor	Endocrinology
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .

OP-3633	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
OP-3633 is a potent and selective steroidal *glucocorticoid receptor* (GR)** antagonist with an IC₅₀ of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism .

Mifepristone-d3 RU486-d₃; RU 38486-d₃	Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay[1].

Mifepristone (Standard) Maximum Cited Publications 35 Publications Verification RU486 (Standard); RU 38486 (Standard)	Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (Standard) is the analytical standard of Mifepristone. This product is intended for research and analytical applications. Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

Mifepristone-d6 RU486-d₆; RU 38486-d₆	Glucocorticoid Receptor Autophagy Endogenous Metabolite NO Synthase Progesterone Receptor Isotope-Labeled Compounds	Endocrinology Cancer
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

PF-3882845	Mineralocorticoid Receptor Progesterone Receptor	Cardiovascular Disease Metabolic Disease
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC₅₀=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to **progesterone receptor (PR) with the binding IC₅₀** of 310 nM .

(Rac)-Finerenone (Rac)-BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal *androgen receptor* (AR)** antagonist with an IC₅₀ of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

Finerenone 2 Publications Verification BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Eplerenone-d3 Epoxymexrenone-d₃	Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch[1][2].

Finerenone-d3 BAY 94-8862-d₃	Mineralocorticoid Receptor	Others
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Finerenone (Standard)	Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Mifepristone-13C,d3 RU486-¹³C,d₃; RU 38486-¹³C,d₃	Isotope-Labeled Compounds Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone- ¹³C,d₃ is the ¹³C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC50s of 0.2 nM and 2.6 nM in in vitro assay[1]. Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Lonaprisan ZK 230211; BAY86 5044	Progesterone Receptor	Endocrinology
Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for **progesterone receptor, with IC₅₀** of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .

Linzagolix choline KLH-2109 choline; OBE-2109 choline	GnRH Receptor	Inflammation/Immunology Cancer
Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2024 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us